Comparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis

Comparison of Outcome Between Oral Methotrexate and Tofacitinib in Treatment of Chronic Plaque Psoriasis

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07581418

Enrollment

Registered

2026-05-12

Start date

2026-06-01

Completion date

2026-12-01

Last updated

2026-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Plaque Psoriasis

Keywords

Psoriasis, Chronic Plaque Psoriasis, Methotrexate, Tofacitinib, Randomized Controlled Trial, Systemic Therapy

Brief summary

This randomized controlled trial aims to compare the efficacy and safety of oral methotrexate and tofacitinib in patients with chronic plaque psoriasis. Participants diagnosed with chronic plaque psoriasis will be randomly assigned to receive either methotrexate or tofacitinib and will be followed for six months. Clinical improvement, disease severity, treatment response, and adverse effects will be assessed and compared between the two treatment groups.

Interventions

DRUGMethotrexate

Oral methotrexate administered according to standard treatment protocol for chronic plaque psoriasis for 8 weeks.

DRUGTofacitinib

Oral tofacitinib administered according to standard treatment protocol for chronic plaque psoriasis for 8 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Eligible participants will comprise adults aged 18 to 70 years, of either gender, with moderate to severe plaque psoriasis defined by a Psoriasis Area and Severity Index (PASI) score greater than 10. A minimum disease duration of 6 months will be required. In addition, enrolment will be limited to patients whose psoriasis has shown inadequate response to at least one topical therapy despite a treatment duration of at least 4 weeks

Exclusion criteria

* Participants with non-plaque variants of psoriasis or any other clinically significant dermatological condition that could confound the assessment of psoriasis severity. Recent exposure to anti psoriatic therapy including systemic or biologic treatment within the preceding 4 weeks or topical treatment within the preceding 2 weeks. Individuals with known hypersensitivity to, or contraindications for, either methotrexate or tofacitinib. Patients with a history of significant hepatic, renal, hematologic, gastrointestinal, or immune system disorders. Pregnant or breastfeeding women. Patients unavoidable prolonged sun or ultraviolet exposure. Patients with a history of alcohol abuse, or other conditions that contraindicate methotrexate use..

Design outcomes

Primary

Measure	Time frame
Change in Psoriasis Area and Severity Index (PASI) score	8 weeks

Contacts

CONTACTAimen Luk

aimanluk0915@gmail.com+923215476167

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 13, 2026